Status: Recruiting
CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Participants needed: 20
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: Huda SalmanUpdated: Jun 24, 2026Locations: 6
Eligibility criteria
Patients must voluntarily sign and date informed consent forms that state his or... [+8]
Pregnant or lactating women. The safety of this therapy on unborn children is no... [+38]